Guerbet Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

David Hale

Geschäftsführender

€1.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	31.7%
Amtszeit als Geschäftsführer	4.5yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	4.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.2yrs

Jüngste Management Updates

Recent updates

Is Guerbet (EPA:GBT) Using Too Much Debt?

Apr 27

Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce

Feb 29

Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report

Mar 28

Is Guerbet (EPA:GBT) A Risky Investment?

Oct 25

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Sep 23

Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?

May 27

We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt

May 04

Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?

Apr 05

Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Mar 19

What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?

Mar 01

When Should You Buy Guerbet SA (EPA:GBT)?

Feb 10

How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 28

Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate

Jan 13

Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?

Dec 23

We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential

Dec 11

Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?

Nov 27

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von David Hale im Vergleich zu den Einnahmen von Guerbet verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2023	€1m	€470k	€24m
Sep 30 2023	n/a	n/a	-€9m
Jun 30 2023	n/a	n/a	-€42m
Mar 31 2023	n/a	n/a	-€42m
Dec 31 2022	€1m	€470k	-€41m
Sep 30 2022	n/a	n/a	-€14m
Jun 30 2022	n/a	n/a	€13m
Mar 31 2022	n/a	n/a	€23m
Dec 31 2021	€2m	€470k	€33m
Sep 30 2021	n/a	n/a	€33m
Jun 30 2021	n/a	n/a	€33m
Mar 31 2021	n/a	n/a	€26m
Dec 31 2020	€933k	€470k	€18m

Vergütung im Vergleich zum Markt: DavidDie Gesamtvergütung ($USD1.59M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt French ($USD529.64K).

Entschädigung vs. Einkommen: DavidDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

David Hale (56 yo)

4.5yrs

Amtszeit

€1,481,777

Vergütung

Mr. David Hale served as Independent Director of Orpea SA since July 28, 2022 until January 2024. He has been Chief Executive Officer of Guerbet SA since January 1, 2020 and serves as its MD & GM. Mr. Hale...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
David Hale	CEO, MD & GM	4.5yrs	€1.48m	keine Daten
Philippe Bourrinet	Chief Pharmacist	4.5yrs	€11.50k	keine Daten
Jerome Estampes	CFO and Senior VP of Business Development & Licensing	5.3yrs	keine Daten	keine Daten
Sarah Dayre	Senior VP of Technical Operations & Interim Chief Pharmacist	3.4yrs	keine Daten	keine Daten
Charlotte Bamiere	Director of Legal Affairs	8.5yrs	keine Daten	keine Daten
Christine Allard	Senior Vice President of Public Affairs & Corporate Communications	no data	keine Daten	keine Daten
Eva Ohlsson	Senior Vice President of Human Resources	no data	keine Daten	keine Daten
Jean-Francois Blanc	Senior Vice President of Interventional Imaging	3.5yrs	keine Daten	keine Daten
Francois Nicolas	Senior VP of R&D	6.8yrs	keine Daten	keine Daten
Valérie Brissart	Senior Vice President of Diagnostic Imaging	4.5yrs	keine Daten	keine Daten
Mathieu Elie	Senior Vice President of Commercial Operations - Asia-Pacific	4.5yrs	keine Daten	keine Daten
Gitte Hesselholt	Senior Vice President of Commercial Operations - Americas & EMEA	4.5yrs	keine Daten	keine Daten

4.5yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: GBTDas Führungsteam des Unternehmens gilt als erfahren (4.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Michel Guerbet	Honorary Chairman	no data	€18.96k	55.13% € 252.4m
Hugues Lecat	Chairman of the Board	less than a year	keine Daten	keine Daten
Claire Jouault-Massiot	Non-Independent Director	11.2yrs	€27.60k	keine Daten
Mark Fouquet	Non-Independent Director	10.2yrs	€27.60k	keine Daten
Didier Izabel	Independent Director	10.2yrs	€109.68k	keine Daten
Céline Lamort	Non-Independent Director	9.2yrs	€27.60k	keine Daten
Nicolas Louvet	Non-Independent Director	8.2yrs	€26.40k	keine Daten
Eric Guerbet	Non-Independent Director	7.2yrs	€27.60k	keine Daten
Jean-Sebastien Raynaud	Employee Director	3.8yrs	keine Daten	keine Daten
Olivier Fougère	Employee Director	3.3yrs	keine Daten	keine Daten
Marc Massiot	Non-Independent Director	3.2yrs	€20.40k	keine Daten
Carine Dagommer	Non-Independent Director	2.2yrs	€25.20k	keine Daten

7.2yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrener Vorstand: GBTDie Vorstandsmitglieder gelten als erfahren (7.1 Jahre durchschnittliche Amtszeit).

Guerbet Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Guerbet SA Announces Board Changes

Guerbet SA, Annual General Meeting, May 24, 2024

Guerbet Announces Management Appointments

Guerbet SA, Annual General Meeting, May 26, 2023

Guerbet Announces Appointment of Charlotte Bamière, General Counsel, to the Executive Committee

Guerbet SA, Annual General Meeting, May 28, 2021

Recent updates

Guerbet SA Announces Board Changes

Is Guerbet (EPA:GBT) Using Too Much Debt?

Guerbet SA Provides Earnings Guidance for the Year 2024

Dividend of €0.50 announced

Price target increased by 22% to €36.38

Further Upside For Guerbet SA (EPA:GBT) Shares Could Introduce Price Risks After 48% Bounce

New minor risk - Share price stability

Returns On Capital At Guerbet (EPA:GBT) Paint A Concerning Picture

Price target increased by 8.4% to €20.68

Guerbet SA (EPA:GBT) Screens Well But There Might Be A Catch

Guerbet SA, Annual General Meeting, May 24, 2024

First half 2023 earnings released: EPS: €0.16 (vs €0.26 in 1H 2022)

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Guerbet Announces Management Appointments

Applied Radiology and Guerbet Launch 'Elucirem (Gadopiclenol) Injection

Full year 2022 earnings released: €3.25 loss per share (vs €2.59 profit in FY 2021)

Price target decreased by 14% to €20.65

Consensus EPS estimates fall by 26%

Guerbet Releases First Production Batch of Elucirem (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging

Guerbet SA, Annual General Meeting, May 26, 2023

Price target decreased to €23.94

Consensus forecasts updated

Price target decreased to €26.82

First half 2022 earnings released: EPS: €0.26 (vs €1.86 in 1H 2021)

Price target decreased to €30.90

Consensus forecasts updated

Price target decreased to €32.80

Guerbet Announces U.S. Food and Drug Administration (FDA) Approval of Elucirem (Gadopiclenol)

Price target decreased to €31.55

Guerbet SA's (EPA:GBT) Intrinsic Value Is Potentially 92% Above Its Share Price

Guerbet SA Confirms Revenue Guidance for the Year of 2022

Price target decreased to €36.18

Upcoming dividend of €0.85 per share

Guerbet Sa Provides Revenue Guidance for 2022

Guerbet Announces Appointment of Charlotte Bamière, General Counsel, to the Executive Committee

Guerbet Recently Submitted New Drug Application to the U.S. Food and Drug Administration

Full year 2021 earnings: Revenues in line with analyst expectations

Analysts Have Been Trimming Their Guerbet SA (EPA:GBT) Price Target After Its Latest Report

Is Guerbet (EPA:GBT) A Risky Investment?

First half 2021 earnings released

Guerbet Provides Group Earnings Guidance for the Year 2021

The Returns On Capital At Guerbet (EPA:GBT) Don't Inspire Confidence

Price target increased to €33.75

Consensus forecasts updated

Upcoming dividend of €0.70 per share

Is Now The Time To Look At Buying Guerbet SA (EPA:GBT)?

We Think Guerbet (EPA:GBT) Is Taking Some Risk With Its Debt

Is Guerbet SA (EPA:GBT) A Good Fit For Your Dividend Portfolio?

Full year 2020 earnings released

Guerbet SA's (EPA:GBT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

What Type Of Shareholders Make Up Guerbet SA's (EPA:GBT) Share Registry?

New 90-day low: €29.85

Analysts update estimates

Guerbet SA to Report Fiscal Year 2020 Results on Mar 24, 2021

When Should You Buy Guerbet SA (EPA:GBT)?

How Much Did Guerbet's(EPA:GBT) Shareholders Earn From Share Price Movements Over The Last Three Years?

Guerbet SA, Annual General Meeting, May 28, 2021

New 90-day high: €35.65

Guerbet SA (EPA:GBT) Shares Could Be 25% Above Their Intrinsic Value Estimate

Would Guerbet SA (EPA:GBT) Be Valuable To Income Investors?

New 90-day high: €33.10

We Think Guerbet's (EPA:GBT) Statutory Profit Might Understate Its Earnings Potential

Guerbet SA Receives Us Food and Drug Administration Approval for the Commercial Sale of the Optiray Imaging Bulk Package (IBP)

Do Its Financials Have Any Role To Play In Driving Guerbet SA's (EPA:GBT) Stock Up Recently?

New 90-day high: €30.00

Analysts lower EPS estimates to €1.64

Price target lowered to €31.00

First half earnings released

Analysts lower EPS estimates to €1.98